Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Nautilus Biotechnology, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
4
| McIlwain Matthew S (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/16/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/16/2023 |
4
| Pande Vijay Satyanand (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/16/2023 |
4
| Epperly Melissa B, (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/16/2023 |
4
| NAZEM FARZAD (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/16/2023 |
4
| Akinsanya Karen (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/15/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/01/2023 |
4
| Patel Sujal M (CEO, President, and Secretary) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 650,000 options to buy
@ $2, valued at
$1.3M
|
|
| 03/01/2023 |
4
| Mowry Anna (CFO and Treasurer) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
| 03/01/2023 |
4
| Murphy Matthew B. (General Counsel) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
| 03/01/2023 |
4
| Godwin Mary E. (Senior VP, Operations) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
| 03/01/2023 |
4
| Mallick Parag (Chief Scientist) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 280,000 options to buy
@ $2, valued at
$560k
|
|
| 03/01/2023 |
4
| Weld Gwen E (Chief People Officer) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
| 03/01/2023 |
4
| Nelson Nicholas A. (CBO & Senior VP, Bus. Dev.) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
| 03/01/2023 |
4
| Sankar Subramanian (Senior VP, Product Development) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
| 03/01/2023 |
SC 13D/A
| Nautilus Biotechnology, Inc. reports a 15% stake in Nautilus Biotechnology, Inc. |
| 02/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/28/2022 |
4
| Sankar Subramanian (Senior VP, Product Development) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 10,000 shares
@ $2.025, valued at
$20.3k
Bought 5,000 shares
@ $2.0298, valued at
$10.1k
|
|
| 09/26/2022 |
4
| Weld Gwen E (Chief People Officer) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 30,000 shares
@ $2.0255, valued at
$60.8k
|
|
| 09/19/2022 |
4
| Sankar Subramanian (Senior VP, Product Development) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 40,000 shares
@ $2.1938, valued at
$87.8k
Bought 35,000 shares
@ $2.1556, valued at
$75.4k
|
|
| 08/22/2022 |
4
| Mowry Anna (CFO and Treasurer) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 17,500 shares
@ $2.2982, valued at
$40.2k
|
|
| 08/16/2022 |
4
| Murphy Matthew B. (General Counsel) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 2,500 shares
@ $2.85, valued at
$7.1k
Bought 7,500 shares
@ $2.841, valued at
$21.3k
|
|
| 08/09/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/08/2022 |
4
| Patel Sujal M (CEO, President, and Secretary) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 41,654 shares
@ $2.9204, valued at
$121.6k
Bought 8,346 shares
@ $2.9288, valued at
$24.4k
|
|
| 08/03/2022 |
4
| Godwin Mary E. (Senior VP, Operations) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 08/02/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/02/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/02/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|